Microcap Ledger Sonoma Pharmaceuticals, Inc. $SNOA
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Capital Market
- Sector
- Surgical & Medical Instruments & Apparatus
- Headquarters
- Boulder, CO
- Fiscal year end
- March 31
- Shares outstanding
- 4,788,425 [10-Q 2026-08-06]
What the company doesAI summary of filing
Sonoma Pharmaceuticals develops and manufactures stabilized hypochlorous acid (HOCl) products for wound care, dermatology, eye care, podiatry, animal health, and surface disinfection. The company sells its products as medical devices in over 55 countries, either directly or through distribution partners. Sonoma generates revenue from product sales and holds 22 FDA clearances for various medical device indications. The company is revenue-generating with a focus on expanding its distribution network and product portfolio across multiple geographic markets and customer channels. [10-K 2026-06-16]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 3 months to Jun 2026 | $6.41M | −$330.0K | −$649.0K | $5.34M | [10-Q 2026-08-06] |
| FY ended Mar 2026 | $19.53M | $3.2K | −$3.93M | $2.40M | [10-K 2026-06-16] |
| FY ended Mar 2025 | $14.29M | $3.5K | −$88.0K | $5.37M | [10-K 2026-06-16] |
- Quarterly cash burn
- −$649.0K
- Cash runway Estimate
- ~24.7 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-11-07 | 1,339,170 | [10-Q 2024-11-07] |
| 2025-02-04 | 1,615,765 | [10-Q 2025-02-05] |
| 2025-06-16 | 1,642,765 | [10-K 2025-06-17] |
| 2025-08-07 | 1,643,265 | [10-Q 2025-08-07] |
| 2025-11-03 | 1,701,076 | [10-Q 2025-11-04] |
| 2026-02-09 | 1,730,613 | [10-Q 2026-02-10] |
| 2026-06-15 | 4,785,801 | [10-K 2026-06-16] |
| 2026-08-06 | 4,788,425 | [10-Q 2026-08-06] |
- Shelf registration
- S-1 filed 2026-04-17; declared effective 2026-04-23 [S-1 2026-04-17]
Listing status
Current status: No Form 8-K Item 3.01 (listing notice) filings in the last 24 months, as of 2026-10-11.
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-10-06 | 8-K | Material agreement entered; Change to security holder rights; Charter, bylaws or fiscal year change |
| 2026-09-17 | 8-K | Shareholder vote results |
| 2026-08-19 | 8-K | Shareholder vote results |
| 2026-08-06 | 10-Q | Quarterly report |
| 2026-07-28 | DEF 14A | Proxy statement |
| 2026-06-18 | 8-K | Other events |
| 2026-06-18 | 424B5 | Prospectus or prospectus supplement |
| 2026-06-16 | 10-K | Annual report |
| 2026-05-05 | DEF 14A | Proxy statement |
| 2026-04-30 | 8-K | Material agreement entered; Other events |
| 2026-04-27 | 424B4 | Prospectus or prospectus supplement |
| 2026-04-27 | PRE 14A | Proxy statement |
Alerts for $SNOA
Email me when Sonoma Pharmaceuticals, Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.